XERS
Xeris Biopharma Holdings, Inc.Healthcare · $1.6B market cap
Verdict
We can't put a fair value on XERS right now. Its earnings are too small compared with its share price for an earnings-based value to mean anything.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow XERS
Track it on your watchlist and see the full analysis. Free.
Create a free accountSuperinvestors
None of the investors we track holds XERS right now. In Q1 2026, 1 sold out. Who we track
Moves in Q1 2026
Sold out: Polen Capital Management
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works